IRIS
PISTELLI, MIRCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.026
EU - Europa 380
AS - Asia 177
AF - Africa 29
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 1.619
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.026
IT - Italia 87
SE - Svezia 69
IE - Irlanda 68
SG - Singapore 63
CN - Cina 60
UA - Ucraina 57
DE - Germania 35
HK - Hong Kong 24
CI - Costa d'Avorio 22
FR - Francia 17
GB - Regno Unito 16
TR - Turchia 16
DK - Danimarca 14
FI - Finlandia 10
KR - Corea 8
MA - Marocco 7
BE - Belgio 4
BR - Brasile 4
IN - India 4
EU - Europa 2
JP - Giappone 2
AT - Austria 1
AU - Australia 1
NL - Olanda 1
RO - Romania 1
Totale 1.619
Salva come PNG Salva come JPEG
Città #
Chandler 170
Jacksonville 89
Ashburn 83
Fairfield 80
Dublin 67
Boardman 55
Des Moines 54
Houston 41
New York 40
Woodbridge 40
Seattle 38
Wilmington 38
Singapore 31
Cambridge 27
Hong Kong 24
Abidjan 22
Lawrence 22
Princeton 22
Ann Arbor 21
San Mateo 20
Centro 15
Beijing 12
San Diego 12
Turin 9
Washington 9
Porto 8
Cagliari 6
Dallas 6
Cantu 5
Chiaravalle 5
Falls Church 5
Brussels 4
Guangzhou 4
Prescot 4
Pune 4
Rome 4
Helsinki 3
Kilburn 3
London 3
Wuhan 3
Yiwu 3
Caserta 2
Chengdu 2
Hangzhou 2
Los Angeles 2
Marche 2
Osimo 2
Qingdao 2
Recanati 2
Redmond 2
Redwood City 2
Southwark 2
São Paulo 2
Ancona 1
Arqua Petrarca 1
Avant-lès-marcilly 1
Baoding 1
Brisbane 1
Cedar Knolls 1
Civitanova Marche 1
Clifton 1
Dalian 1
Dangan 1
Duncan 1
Handan 1
Hounslow 1
Jinhua 1
Mestre 1
Newark 1
Norwalk 1
Nossa Senhora do Socorro 1
Philadelphia 1
Phoenix 1
San Costanzo 1
Santa Maria 1
Scafati 1
Shanghai 1
Shaoxing 1
Shenzhen 1
Sioux Falls 1
Suzhou 1
Verona 1
Vienna 1
Wuxi 1
Xi'an 1
Zhengzhou 1
Zhuhai 1
Totale 1.169
Salva come PNG Salva come JPEG
Nome #
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 106
Role of DCE-MR in predicting breast cancer subtypes. 104
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 99
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 94
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 90
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review 90
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 89
Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit? 77
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 77
Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report 76
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 75
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 72
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 70
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 66
Expectations and psychological issues before genetic counseling: analysis of distress determinant factors 65
Adjuvant Systemic Therapy in DCIS 65
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 61
The impact of lifestyle interventions in high‐risk early breast cancer patients: A modeling approach from a single institution experience 61
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 57
Espressione di p-mTOR e del recettore degli androgeni nei tumori mammari triplo negativi: significato clinico e potenziali prospettive terapeutiche 53
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 51
A Mixed-apprOach program To help women wIth breast cancer stay actiVE (MOTIVE program): A pilot-controlled study 50
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 18
Totale 1.666
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.585
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.585
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202091 0 0 0 0 0 0 10 4 11 14 15 37
2020/2021355 30 34 64 1 29 26 22 28 32 39 33 17
2021/2022184 12 28 4 1 2 29 11 9 17 22 17 32
2022/2023455 31 58 30 49 27 99 0 15 97 2 24 23
2023/2024242 46 3 16 17 33 70 4 16 0 3 0 34
2024/2025196 65 45 11 9 24 12 30 0 0 0 0 0
Totale 1.666